ABCG2 and neoplasm: Very recently, telatinib (15 mg/kg) in combination with doxorubicin (1.8 mg/kg) was shown to significantly decrease the growth rate and tumor size of ABCG2-overexpressing tumors in a xenografted nude mouse model [26].